Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 01/16/2026 | CALL | $820.00 | 314 | +300 | +2,142.86% |
| 06/20/2025 | CALL | $590.00 | 326 | +288 | +757.89% |
| 01/16/2026 | CALL | $830.00 | 165 | +138 | +511.11% |
| 12/19/2025 | PUT | $480.00 | 119 | +100 | +526.32% |
| 12/19/2025 | CALL | $680.00 | 113 | +97 | +606.25% |
| 12/19/2025 | CALL | $600.00 | 109 | +82 | +303.70% |
| 05/16/2025 | CALL | $680.00 | 33 | -4 | -10.81% |
| 06/20/2025 | PUT | $660.00 | 386 | -6 | -1.53% |
| 05/16/2025 | PUT | $620.00 | 19 | -7 | -26.92% |
| 05/16/2025 | PUT | $600.00 | 327 | -11 | -3.25% |
| 05/16/2025 | PUT | $580.00 | 250 | -15 | -5.66% |
| 05/16/2025 | CALL | $580.00 | 308 | -24 | -7.23% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.88% | 3.09M | 2.22B |
| Growth Fund Of America Inc | 2.66% | 2.86M | 2.05B |
| Fidelity Contrafund Inc | 2.41% | 2.59M | 1.86B |
| Vanguard 500 Index Fund | 2.30% | 2.48M | 1.78B |
| Vanguard Specialized-Health Care Fund | 1.42% | 1.52M | 1.09B |
| Dodge & Cox Stock Fund | 1.32% | 1.42M | 1.02B |
| Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 1.31% | 1.41M | 1.02B |
| JP Morgan Large Cap Growth Fund | 1.21% | 1.3M | 935.63M |
| New Perspective Fund Inc | 1.11% | 1.19M | 857.04M |
| Fidelity 500 Index Fund | 1.09% | 1.17M | 843.36M |
Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025
05/15 08:48 am
Investing.com
Read moreBlood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight
05/12 01:00 pm
GlobeNewswire Inc.
Read moreGeneric Oncology Drugs Market Size Estimated to Reach USD 30,998 Mn by 2034, Rising Global Cancer Cases Increase Demand for Affordable Treatments
05/07 11:00 am
GlobeNewswire Inc.
Read moreGiants of Cancer Care® announces the 13th annual class of inductees
05/07 09:00 am
GlobeNewswire Inc.
Read moreMarket Sell-Off: 2 Stocks Down 17% and 36% This Year to Buy and Hold
04/26 09:30 am
The Motley Fool
Read moreRegeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines
04/22 06:00 am
GlobeNewswire Inc.
Read moreAtopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market
04/18 04:26 am
GlobeNewswire Inc.
Read moreFDA Sets The Countdown: Regeneron's Eylea HD Could Be Headed For Major Expansion
04/17 12:06 pm
Benzinga
Read moreSanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study
04/15 02:08 pm
Benzinga
Read moreBiopharmaceuticals Global Overview Report 2025: Global Market to Reach $698.7 Billion by 2030, Fueled by Specialized Therapies, Such as mAb and Gene Treatments, & a Strong Pipeline
04/10 05:59 am
GlobeNewswire Inc.
Read moreIs Vertex Pharmaceuticals Stock a Buy?
04/08 09:45 am
The Motley Fool
Read more3 Growth Stocks That Have Turned $1,000 Into More Than $100,000 in 20 Years
04/05 03:23 am
The Motley Fool
Read moreWhy Pharma and Biotech Stocks Got Thrashed on Tuesday
03/25 06:47 pm
The Motley Fool
Read moreRegeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
03/11 09:32 pm
GlobeNewswire Inc.
Read moreREGN DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action – REGN
03/10 04:47 pm
GlobeNewswire Inc.
Read moreAmgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study
03/10 12:50 pm
Benzinga
Read more1 Dividend Stock Down 30% to Buy and Hold for the Next Decade
03/09 06:20 am
The Motley Fool
Read moreRegeneron’s (REGN) Transparency Questioned as Investors Sue Over Eylea Pricing Practices– Hagens Berman
03/06 02:53 pm
GlobeNewswire Inc.
Read moreGlobal Genome Editing Market to Grow Rapidly at a CAGR ~13% by 2032 | DelveInsight
03/06 02:00 pm
GlobeNewswire Inc.
Read moreDeadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
03/05 01:00 pm
GlobeNewswire Inc.
Read morePhysicians’ Education Resource® unveils Retina Resource, a comprehensive educational hub for retina specialists and eye care professionals
03/05 11:00 am
GlobeNewswire Inc.
Read moreREGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
03/04 05:00 pm
GlobeNewswire Inc.
Read moreRegeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts – Hagens Berman
03/02 02:11 pm
GlobeNewswire Inc.
Read moreREGN FINAL DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action – REGN
03/01 04:13 pm
GlobeNewswire Inc.
Read moreREGN 最終截止日期：全國知名投資者法律顧問 ROSEN 鼓勵損失 10 萬美元以上的 Regeneron Pharmaceuticals, Inc. 投資者在對 REGN 提出證券集體訴訟的重要截止日期 3 月 10 日前聘請律師
03/01 04:13 pm
GlobeNewswire Inc.
Read moreInternational Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month
03/01 09:45 am
GlobeNewswire Inc.
Read moreOPZELURA Continues to Revolutionize Dermatology Market with Strong Market Uptake | DelveInsight
02/28 02:00 pm
GlobeNewswire Inc.
Read moreLinvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
02/28 08:00 am
GlobeNewswire Inc.
Read moreDeadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
02/27 01:00 pm
GlobeNewswire Inc.
Read moreREGN DEADLINE ALERT: Regeneron Pharmaceuticals (REGN) Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 10th Deadline in Securities Class Action
02/26 09:10 pm
GlobeNewswire Inc.
Read moreOdronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma
02/26 08:00 am
GlobeNewswire Inc.
Read moreLAG-3 Immunotherapies Market Set for Rapid Growth in the Coming 10 Years Across the 7MM as Next-Generation Therapies Advance | DelveInsight
02/25 02:00 pm
GlobeNewswire Inc.
Read moreROSEN, LEADING INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN
02/23 03:03 pm
GlobeNewswire Inc.
Read moreDeadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
02/21 01:00 pm
GlobeNewswire Inc.
Read moreROSEN, LEADING TRIAL ATTORNEYS, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN
02/20 08:26 pm
GlobeNewswire Inc.
Read moreREGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
02/20 05:00 pm
GlobeNewswire Inc.
Read moreChronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight
02/20 02:00 pm
GlobeNewswire Inc.
Read moreDEADLINE ALERT for NXT, RVNC, REGN, BIOA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
02/19 01:00 pm
GlobeNewswire Inc.
Read moreREGN STOCK NEWS: Robbins LLP Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Lead Plaintiff Deadline – March 4, 2025
02/18 08:53 pm
GlobeNewswire Inc.
Read moreThis Company Just Initiated a Quarterly Dividend: Time to Buy?
02/18 10:45 am
The Motley Fool
Read moreDupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
02/18 01:59 am
GlobeNewswire Inc.
Read moreROSEN, A GLOBALLY RESPECTED LAW FIRM , Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN
02/17 03:53 pm
GlobeNewswire Inc.
Read moreREGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
02/14 05:00 pm
GlobeNewswire Inc.
Read moreAnalyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit– Hagens Berman
02/12 07:57 pm
GlobeNewswire Inc.
Read moreROSEN, A LEADING LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN
02/11 10:04 pm
GlobeNewswire Inc.
Read moreAnalyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit– Hagens Berman
02/10 02:48 pm
GlobeNewswire Inc.
Read moreDEADLINE ALERT for NXT, RVNC, REGN, BIOA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
02/10 01:00 pm
GlobeNewswire Inc.
Read moreInvesting $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move
02/10 07:15 am
The Motley Fool
Read moreROSEN, A LEADING LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN
02/09 12:34 am
GlobeNewswire Inc.
Read moreEYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting
02/08 06:40 pm
GlobeNewswire Inc.
Read more